Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$2.2MCash on Hand
3.9mo Cash Runway
5.5%Short Interest
$15.5Analyst Target (2)
Follow BCDA by emailGet an email when BCDA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about BCDA, unsubscribe in one click. Privacy
📣 What BCDA Says Is Next
first quarter of 2027 · “With FDA alignment on the De Novo approval pathway for Helix, we expect to complete the De Novo submission in the first quarter of 2027 with approval in mid-2027 if FDA meets its official target goal of 150 review days under Medical Device User Fee Amendments (MDUFA) guidelines.”
Company press release, Nov 12, 2026 · SEC filing
this quarter · “BioCardia expects FDA substantive review with written feedback, followed by a meeting with BioCardia to discuss approval via the De Novo pathway, this quarter.”
Company press release, Oct 19, 2026 · SEC filing
this Quarter · “ex_1027387.htm Exhibit 99.1 BioCardia Announces FDA Acceptance of De Novo Pre-Submission Package for Helix TM Catheter Marketing Clearance FDA Substantive Review and Meeting Expected this Quarter October 19, 2026, Sunnyvale, Calif.”
Company press release, Oct 19, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 12, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 12, 2026 ·
Earnings Reported Q3 2026 results: net cash used in operations of $1.7 million, cash of $2.2 million with runway into 2027, and a net loss of $1.8 million. Japan PMDA submission process completed, with Helix FDA De Novo submission expected Q1 2027. Form 8-K · SEC filing · Press release
Nov 6, 2026 ·
Regulatory Completed the clinical consultation process with Japan's PMDA on CardiAMP Cell Therapy System for ischemic heart failure, advancing toward a marketing approval application. Completion does not constitute regulatory approval. Targets first Japan patients and commercial revenues in 2028. Form 8-K · SEC filing · Press release
Oct 19, 2026 ·
Regulatory FDA accepted BioCardia's revised De Novo pre-submission package for its Helix transendocardial catheter. The company expects FDA substantive review with written feedback and a meeting to discuss De Novo approval this quarter. Form 8-K · SEC filing · Press release
Oct 7, 2026 ·
Presents the design of the CardiAMP HF II trial, a confirmatory study of high dose autologous cell treatment in ischemic heart failure with reduced ejection fraction, at the HFSA Annual Scientific Meeting in Phoenix, October 9 to 12, 2026. FDA recently agreed the trial may be sufficient to support approval. Form 8-K · SEC filing · Press release
Oct 1, 2026 ·
Regulatory BioCardia completed a revised Pre-Submission to FDA CDRH under its Q-Submission program for its Helix Catheter for delivering therapeutic and diagnostic agents to the heart. The FDA targets an initial acceptance or refusal review within 15 calendar days. Form 8-K · SEC filing · Press release
Sep 21, 2026 ·
Listing BioCardia regained compliance with the Nasdaq $1.00 minimum bid price requirement after its stock closed at or above $1.00 for at least 10 consecutive business days, and Nasdaq closed the matter. The company warned it cannot assure it will stay compliant. Form 8-K · SEC filing
Sep 10, 2026 ·
Peter Altman, CEO, will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York, September 14-16, 2026, with a prerecorded presentation available from September 11. Form 8-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Dec 2026 · Phase 1/2 · Active Trial · Clinical Trial of Human Allogenic Culture-expanded Bone Marrow-derived Mesenchymal Stem Cells Registry primary completion date, not a results date
Apr 2027 · N/A · Recruiting · CardiAMP Heart Failure II Trial for Patients With Ischemic Heart Failure With Reduced Ejection Fraction Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
BCDA holds $2.2M in cash and short-term investments (as of Sep 30, 2026) and burns about $1.7M/quarter from operations,
an estimated runway of 3.9 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:90 · High
Cash runway 4 months +40
ATM program on file since Oct 2025 +15
Going-concern doubt in the latest 10-Q +15These factors raise substantial doubt about our ability to continue as a going concern beyond one year from the date these financial statements are issued.10-Q, Nov 2026
Share count 15,138,782 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
📈 Recent Insider Activity (Form 4)
Trade date
Insider
Transaction
Shares
Price
Owned after
2026-10-16 filed 2026-10-20
Altman Peter
Purchase (P)
300
$0.95
385,385
2026-10-15 filed 2026-10-20
Altman Peter
Purchase (P)
200
$0.95
385,085
2026-09-23 filed 2026-09-23
Altman Peter
Purchase (P)
1,900
$1.05
383,885
2026-09-03 filed 2026-09-04
Altman Peter
Purchase (P)
800
$1.09
381,985
2026-08-17 filed 2026-08-18
Altman Peter
Purchase (P)
5,400
$0.93
381,115
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
Get the full BCDA picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BCDA and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.